Details of the Drug Combination

General Information of Drug Combination (ID: DC7WKOI)

Drug Combination Name
Bifemelane OZ277
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs Bifemelane   DMU73F0 OZ277   DM1YB0R
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 2.414
Bliss Independence Score: 3.346
Loewe Additivity Score: 2.828
LHighest Single Agent (HSA) Score: 1.183

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bifemelane
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Terminated [2]
Bifemelane Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Bifemelane Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [4]
------------------------------------------------------------------------------------
Indication(s) of OZ277
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [3]
OZ277 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) TTZVSJ2 NOUNIPROTAC Inhibitor [3]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
3 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.